Table 5. Cell biological feature related oncogenic functional connectivity map (pathway based) statistics.
Name of Pathway | Network statistics |
|||||||
---|---|---|---|---|---|---|---|---|
CPN | CGH | CSV | CMG | CML | CIV | CAH | OVP | |
Actin cytoskeletal regulation | N-7, E-7 | |||||||
Adherens junction | N-8, E-9 | N-8, E-12 | N-9, E-10 | N-4, E-3 | N-8, E-13 | |||
Alpha6 Beta4 mediated signaling | N-11, E-21 | N-6, E-6 | N-7, E-10 | |||||
Androgen receptor mediated signaling | N-11, E-21 | N-12, E-24 | N-9, E-16 | N-7, E-8 | N-9, E-17 | N-3, E-2 | ||
ARF6 trafficking event | N-16, E-31 | |||||||
ATM dependent DNA damage response | N-8, E-9 | N-6, E-5 | ||||||
Chemokine mediated signaling | N-11, E-18 | N-8, E-6 | N-8, E-8 | |||||
Chronic myeloid leukemia pathogenesis | N-8, E-8 | N-6, E-5 | ||||||
Class I PI3K mediated signaling | N-30, E-56 | N-21, E-28 | ||||||
Colorectal cancer pathogenesis | N-8, E-9 | N-10, E-15 | N-4, E-3 | N-8, E-9 | ||||
EGFR mediated signaling | N-8, E-7 | N-13, E-28 | N-3, E-2 | N-11, E-15 | ||||
Estrogen receptor mediated signaling | N-31, E-59 | N-8, E-9 | N-10, E-10 | |||||
Endometrial cancer associated pathogenesis | N-7, E-7 | |||||||
ERBB mediated signaling | N-8, E-7 | N-11, E-18 | N-6, E-7 | |||||
Focal Adhesion | N-9, E-11 | N-14, E-31 | N-8, E-8 | N-8, E-10 | N-9, E-13 | N-8, E-11 | N-4, E-4 | N-7, E-7 |
Glioma associated pathogenesis | N-7, E-7 | |||||||
HGF mediated signaling | N-8, E-10 | |||||||
IGF1 mediated signaling | N-7, E-6 | |||||||
IFN-gamma signaling | N-17, E-35 | N-10, E-14 | ||||||
IL-2 mediated signaling | N-4, E-3 | |||||||
IL-3 mediated signaling | N-11, E-21 | N-6, E-5 | N-9, E-11 | |||||
IL-5 mediated signaling | N-10, E-15 | N-5, E-4 | ||||||
IL-6 mediated signaling | N-13, E-27 | N-4, E-3 | N-6, E-6 | |||||
IL-11 mediated signaling | N-6, E-5 | |||||||
Insulin mediated signaling | N-6, E-5 | N-8, E-7 | ||||||
Integrin mediated cell adhesion | N-7, E-10 | |||||||
Kit receptor associated signaling | N-9, E-18 | N-5, E-4 | ||||||
Leptin signaling | N-8, E-6 | N-9, E-11 | ||||||
MAPK signaling | N-7, E-5 | N-6, E-5 | ||||||
Melanoma pathogenesis | N-7, E-6 | |||||||
Neurotrophin signaling | N-8, E-7 | N-5, E-5 | ||||||
Oncostatin M signaling | N-7, E-8 | |||||||
Pancreatic cancer pathogenesis | N-12, E-13 | N-6, E-5 | N-7, E-5 | N-5, E-3 | ||||
p75(NTR) mediated signaling | N-8, E-7 | N-7, E-5 | ||||||
Prolactin signaling | N-12, E-12 | N-10, E-15 | N-3, E-2 | |||||
TGF beta associated signaling | N-9, E-8 | N-12, E-20 | N-8, E-6 | N-9, E-12 | N-8, E-9 | |||
TRAIL signaling | N-9, E-9 | |||||||
VEGF signaling | N-5, E-4 | N-6, E-5 | ||||||
Wnt signaling | N-10, E-10 | N-8, E-8 | ||||||
uPAR mediated signaling | N-21, E-28 |
Abbreviations: CPN-Cell proliferation, CGH-Cell growth, CSV-Cell survival, CMG-Cell migration, CML-Cell motility, CIV-Cell invasion, CAH-Cell adhesion, OVP-Overexpression, N-Node, number of protein present in the corresponding network, E-Edge, number of binary [physical] interactions between the proteins present in the corresponding network.